Alerts
Drug & Safety Alerts
What is on the street right now and how to stay safer. Fentanyl and xylazine adulterants, regional overdose spikes, naloxone access changes, and harm-reduction guidance reviewed by clinicians.
Alerts
FDA Extends Naloxone Shelf Life to 4 Years: What This Means for Overdose Response
The FDA has extended the shelf life of over-the-counter naloxone nasal spray from 3 to 4 years. Here's what families and individuals should know about storage, access, and emergency preparedness.
5m
Alerts
Rhode Island Health Officials Issue Overdose Spike Alert for Johnston and North Providence
RIDOH warns of increased overdose activity in two municipalities that historically have lower-than-average rates. What residents should know and where to find help.
4m
Alerts
DEA Issues Public Safety Advisory on Fentanyl Mixed with Synthetic Tranquilizers and Opioids
Federal drug officials warn that fentanyl is increasingly mixed with xylazine, medetomidine, nitazenes, and cychlorphine — combinations that reduce naloxone effectiveness and increase overdose risk.
8m
Alerts
Nitazene Synthetic Opioids Spreading in Midwest Drug Supply: What to Know About Overdose Response
Public health surveillance has detected nitazene-class synthetic opioids in counterfeit pills and powders across several Midwest states. Naloxone still works, but the response calls for specific steps.
7m
Alerts
Xylazine Detected in Over 60% of Pacific Northwest Fentanyl Samples, DEA Reports
The DEA's Pacific Northwest field division warns that xylazine — a veterinary sedative — is now present in most fentanyl seized in Oregon, Washington, and Idaho. Naloxone still works on the opioid component, but additional risks require attention.
4m